Group Leader/s



The Translational medicinal and biological chemistry group is focused on the design, synthesis, biological evaluation, study and further optimization of pharmacokinetic properties of structurally diverse chemical entities for drug discovery. The efforts of our group are focused on the discovery of innovative drugs with novel mechanism of action as disease-modifying agents for unmet severe pathologies such as neurodegenerative and neglected diseases. Our group applies medicinal chemistry programs combining classical and computational medicinal chemistry.

For the design of our drugs (mainly small heterocyclic molecules with MW<500), different strategies will be used. These include computer-aided drug design, multifunctional compounds bearing different pharmacophore moieties in the same molecule to interact with different targets, and improving ADME properties of the candidates, among others. The group has developed an in-house chemical library (called MBC library) containing over 1200 compounds with privileged scaffolds, which is continuously growing and extensively used in our directed biological and computational screening programs.

Our research is applied with a high content of translational research. The group's research programs are designed from the early stages of drug discovery to proof of efficacy in representative animal models. Scientific collaborations and technology transfer to companies in the pharmaceutical sector are key tasks in achieving our goals.





Martinez, A.; Gil, C.  [2016]. Heterocycles containing nitrogen and sulphur as potent biologically active scaffolds. Privileged Scaffolds in Medicinal Chemistry. Ed. S. Bräse, Royal Society of Chemistry. 231-262.

Sebastian, V.; Manoli, M.-T.; Pérez, D. I.; Gil, C.; Mellado, E.; Martinez, A.; Espeso, E.; Campillo, N. E.  [2016]. New applications for known drugs: Human Glycogen Synthase Kinase 3 inhibitors as modulators of Aspergillus fumigatus growth. Eur. J. Med. Chem. 116, 281-289.

Martín-Requero, A.; Alquézar, C.; Salado, I. G.; de la Encarnación, A.; Pérez, D. I.; Moreno, F.; Gil, C.; López de Munain, A.; Martínez, A.  [2016]. Targeting TDP-43 phosphorylation by Casein Kinase-1δ inhibitors: a novel strategy for the treatment of frontotemporal dementia. Mol. Neurodegener. 11:36.

Mantoani, S.P. ; Perez-Cantuaria, T.; Vilela, A.F.L.; Cardoso, C.L.; Martínez, A.; Carvalho I.  [2016]. Novel Triazole-quinoline Derivatives as Dual Binding Site Acetylcholinesterase Inhibitors for Alzheimer Treatment. Molecules, 21:193

Cheng, Y.; Pardo, M.; de Souza-Armini, R.; Martinez, A.; Moushine, H.; Zagury, J.F.; Jope, R.S.; Beurel E.  [2016]. Stress-induced neuroinflammation is mediated by GSK3-dependent TLR4 signaling that promotes susceptibility to depression-like behavior. Brain, Behav., Immun. pii: S0889-1591(15)30074-X

Concetta Di Martino, R.M.; De Simone, A.; Andrisano, V.; Bisignano, P.; Bisi, A.; Gobbi, S.; Rampa, A.; Perez, D.I.; Martinez, A.; Bottegoni, G.; Cavalli, A.; Belluti, F.  [2016]. The versatility of the Curcumin Scaffold: Discovery of Potent and Balanced Dual BACE-1 and GSK-3β Inhibitors. J. Med. Chem. 2016, 59, 531-544.

Garcia, A. M.; Martinez, A.; Gil, C.  [2016]. Enhancing cAMP levels as strategy for the treatment of neuropsychiatric disorders. Curr. Top. Med. Chem. 2016, 16, 3527-3535

Morales-García, J. A.; Echeverry-Alzate, V.; Alonso-Gil, S.; Sanz-SanCristobal, M.; Lopez-Moreno, J. A.; Gil, C.; Martinez, A.; Santos, A.; Perez-Castillo, A.  [2016].  Phosphodiesterase7 inhibition activates adult neurogenesis in the hippocampus and subventricular zone in vitro and in vivo. Stem Cells 2016, doi: 10.1002/stem.2480.

de Munck García, E.; Palomo, V.; Muñoz-Sáez, E.; Perez, D. I.; Gómez Miguel, B.; Solas, M. T.; Gil, C.; Martinez, A.; Arahuetes Portero, R. M.  [2016].  Small GSK-3 inhibitor shows efficacy in a motor neuron disease murine model modulating autophagy. PlosOne. 2016, 11, e01627232.

Pérez, D. I.; Martinez, A.; Gil, C.; Campillo, N. E.  [2015]. From bitopic inhibitors to multitarget drugs for Alzheimer’s disease future treatment. Curr. Med. Chem. 2015, 22, 3789-3806




Multitarget-designed small molecules targeting protein kinase and BACE1: A new approach for prevention and treatment of cognitive disorders (SAF2016-76693-R)

01.01.2017 - 31.12.2019
PI: Dr. Ana Martinez

Strengthening the druggability of protein kinases of Leishmania. Drug discovery of specific parasite protein kinase inhibitors (SAF2015-65740-R)

01.01.2016 - 31.12.2018
PIs: Drs. Carmen Gil and Luis Rivas

From fragments to hits: Exploiting the potential of dynamic combinatorial chemistry in drug discovery (CTQ2015-69643-R)

01.01.2016 - 31.12.2018
PI: Dr. Ruth Pérez Fernández

Chemi-computation to discovery of multitarget drugs for the treatment of Alzheimer's disease (CTQ2015-66313-R)

01.01.2016 - 31.12.2018
PI: Drs. Nuria E. Campillo and Angeles Martín Requero

Eyes: a diagnosis window to the brain (SAF2015-72325-EXP)

01.06.2016 - 31.05.2017
PI: Dr. A. Martinez

Development of innovative therapies for Parkinson’s disease (RTC-2015-3439-1).

01.70-2015 – 31.12-2018
PI: Dr. Ana Martinez

Spanish network of drug discovery (SAF2015-71892-REDT).

MINECO, Redes de Excelencia Program
01.01.-2016 – 31.12.2017
PI (CSIC): Dr. Ana Martínez

Parasite-specific cyclic nucleotide phosphodiesterase inhibitors to target neglected parasitic diseases-PDE4NPD (GA 602666)

UE, FP7-Health Program
1.03.2014 - 28.02.2018
Coordinator: Prof. Rob Leurs (VUA). PI (CSIC): Dr. Carmen Gil

Kinase inhibitors for the treatment of amyotrophic lateral sclerosis (SAF2012-37979-C03-01).

01.01.2013 - 31.12.2016
PI: Dr. Ana Martinez


New pharmacological approaches for Parkinson’s disease treatment (SAF2012-33600)

01.01.2013 - 30.06.2016
PI: Dr. Carmen Gil

Novel potential anti-Alzheimer agents: From design to preclinical studies (i-link0801).

CSIC, i-LINK Program
01.01.2014 - 30.06.2016
PI: Dr. Ana Martinez

Phosphodiesterase inhibitors as potential drugs for the treatment of Parkinson’s disease (PIE-201280E087).

CSIC, Proyectos Intramurales Especiales.
01.06.2012 - 30.05.2015
PI: Dr. Carmen Gil

Development of innovative therapies for the treatment of Parkinson’s disease (IPT-2012-0762-300000)

01.7.2012 - 31.12.2015
Coordinator: Dr. Manuel Sarasa (ARACLON).  PI (CSIC): Dr. Ana Martinez.


More info

Outreach activities


Pint of Science (

Title: Cómo ser un fármaco y no morir en el intento
Carmen Gil and Nuria E. Campillo   

Location: Madrid
Date: 24 Mayo 2016             



“¿Qué sabemos de?” institutional program (

Title: Parkinson y Alzheimer: avances en el tratamiento
Ana Martinez

Location: Lanzarote
Date: 24 Mayo 2016



Title: Parkinson y Alzheimer: avances en el tratamiento
Ana Martinez

Location: Fuerteventura
Date: 25 Mayo 2016


Title: Ciencia y emprendimiento: del laboratorio a la farmacia
Ana Martinez

Location: Madrid
Date: 14 Enero 2016


“Primavera para el recuerdo”
Title: ¿Qué sabemos del Alzheimer? (

Ana Martinez

Location: Huesca
Date: 6 Mayo 2016


“Ciudad Ciencia” institutional program (

Title: ¿Que sabemos del Alzheimer?
Ana Martinez

Location: Plasencia
Date: 13 April 2015


Title: ¿Qué sabemos del Parkisnon?
Ana Martinez

Location: Barbastro
Date: 26 November 2015


Title: ¿Qué sabemos del Parkisnon?
Ana Martinez

Location: Valdepeñas
Date: 10 December 2015



Title: ¿Qué sabemos del Alzheimer?
Ana Martinez
Editorial: CSIC and Catarata ISBN: 978-84-00-08818-7

Title: ¿Qué sabemos del Parkinson?
Carmen Gil and Ana Martinez
Editorial: CSIC and Catarata ISBN: 978-0-470-95917-6.
















10-13/11/2015 Science Week
“Paracetamol synthesis” Hands on workshop with more than 80 High School students.